Observational analysis reveals associations between AT1R and ETAR antibodies, cytokine elevations, suggesting immune dysregulation in pediatric transplant patients.
Activating antibodies to angiotensin II type 1 receptor (AT1R) and endothelin type A receptor (ETAR) have been associated with rejection, allograft loss, decline in allograft function, and development of human leukocyte antigen donor-specific antibodies in kidney transplantation. Understanding immune dysregulation and inflammatory signatures associated with these antibodies is important for generating targeted investigations of pathogenesis. We investigated a panel of 38 cytokines in a multicenter cohort of 133 pediatric kidney transplant recipients with 1 to 2 years of follow up to further elucidate AT1R and ETAR-Ab-associated inflammatory signatures. Pretransplant and posttransplant blood samples (n = 483) were tested for AT1R-Ab, ETAR-Ab, and 38 cytokines. The relationship between AT1R and/or ETAR-Ab positivity and cytokine elevations were evaluated accounting for demographic and clinical factors. AT1R and/or ETAR-Ab positivity was associated with elevations in 33 of the 38 cytokines, with some elevations resolving or intensifying on posttransplant vs pretransplant samples. Interrogation of these data using z-score comparisons and principal component analyses revealed a strong signal for interleukin (IL)-9, IL-13, IL-5, IL-4, IL-6, lymphotoxin α, and granulocyte-macrophage colony-stimulating factor-cytokines involved with antibody formation and type 2 immune responses. The relationship of this signal to transplant outcomes and impact of adjunctive receptor blockade requires additional investigation.
No takes yet. Share an insight, caveat, or question.
Pearl et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: